
Explore the innovative subcutaneous delivery of isatuximab for multiple myeloma, enhancing patient experience and treatment efficiency in the IRAKLIA study.

Explore the innovative subcutaneous delivery of isatuximab for multiple myeloma, enhancing patient experience and treatment efficiency in the IRAKLIA study.

FDA prioritizes review of revumenib for relapsed NPM1-mutant AML, highlighting a breakthrough in targeted cancer therapies.

Perioperative pembrolizumab enhances survival rates in advanced head and neck cancer, paving the way for earlier immunotherapy integration and future treatment strategies.


Dale Shepard, MD, PhD, discusses the key themes emerging from the 2025 ASCO Annual Meeting, highlighting a prevailing sense of optimism driven by ongoing research.


New findings reveal mirvetuximab soravtansine significantly improves outcomes in patients with recurrent platinum-sensitive ovarian cancer, regardless of HRD status.

Erika Hamilton, MD, shares key insights from the 2025 ASCO Annual Meeting that are set to impact breast cancer treatment.

Explore the complexities of chronic GVHD symptoms, assessment, and innovative treatment strategies, including ruxolitinib and emerging therapies.

New trial results reveal zanzalintinib and atezolizumab significantly enhance survival in metastatic colorectal cancer, marking a breakthrough in treatment options.

FDA accelerates approval of datopotamab deruxtecan for advanced EGFR-mutated NSCLC, offering new hope for previously treated patients.

Pirtobrutinib shows significant benefits in progression-free survival and tolerability for relapsed CLL patients compared to standard treatments.

Asciminib shows significant safety and efficacy advantages over nilotinib in treating newly diagnosed chronic myeloid leukemia, promising a new standard of care.

Jeremy S. Abramson, MD, discusses pivotal advancements in DLBCL from the 2025 American Society of Clinical Oncology Annual Meeting.

FDA clears lonitoclax for a phase 1 trial in relapsed/refractory AML, promising improved safety and efficacy over existing therapies.

A groundbreaking trial shows promising survival rates and low GVHD in patients receiving mismatched stem cell transplants, expanding treatment options for diverse populations.

Explore the complexities of non-clear cell renal cell carcinoma, its treatment challenges, and promising immunotherapy advancements for better patient outcomes.

Alicia Morgans, MD, MPH, discusses a potentially practice-changing abstract from the 2025 American Society of Clinical Oncology Annual Meeting: the AMPLITUDE trial.

Recent advances in RAS-targeted therapies revolutionize treatment for gastrointestinal cancers, promising improved outcomes and new clinical strategies for oncologists.

This week in oncology highlights: FDA approvals and long-term study results, showcasing advancements in cancer treatments, and patient care strategies.

Shahzad Raza, MD, discusses new data from the phase 2 RedirecTT-1 study of talquetamab with teclistamab for the treatment of patients with relapsed/refractory multiple myeloma and extramedullary disease.

Explore the role of consolidative thoracic radiotherapy in enhancing survival for extensive-stage small cell lung cancer post-chemoimmunotherapy.

Pembrolizumab combined with chemoradiation shows promising long-term efficacy and safety in treating advanced non-small cell lung cancer.

Zanubrutinib shows superior progression-free survival in chronic lymphocytic leukemia compared with acalabrutinib plus venetoclax, according to recent analysis.

Christina Poh, MD, discusses the recent FDA approval of tafasitamab plus lenalidomide and rituximab in relapsed/refractory follicular lymphoma.


New CAR T-cell therapy shows remarkable efficacy in treating relapsed multiple myeloma, achieving high response rates and minimal residual disease negativity.

Early results from the MagnetisMM-6 trial reveal promising efficacy of elranatamab, daratumumab, and lenalidomide in treating newly diagnosed multiple myeloma.

